制癌剤投与における毒性発現の個人差とその対策 Side effects and its prevention in anticancer treatment.:Side effects and its prevention in anticancer treatment

この論文にアクセスする

この論文をさがす

著者

    • 畠 清彦 HATAKE Kiyohiko
    • 財団法人癌研究会付属病院化学療法科 Department of Chemotherapy, Cancer Institute Hospital,Japanese Foundation for Cancer Research, Tokyo

抄録

Anticancer drugs have been developing, and side effects of those drugs should be prevented. Many kinds of side effects have been reported, but we do not predict them. Side effects, including cardiac toxicity, nephrotoxicity, and neurotoxicity are known. As DNA microarray techniques has been developed well it is now applicable to predict side effects using single nucleotide polymorphism (SNP). To prevent side effects, development of new drugs or novel drug delivery system will provide us possibilities for future. Monoclonal antibodies or tyrosine kinase inhibitors are novel modalities to predict efficacy and side effects. Drug resistance or infusion-related syndrome has to be analyzed, For instances, CD 13 is a molecule that degrades the N-terminal residues of endothelial interleukin-8 and will be resistant to apoptotic signal. In this case we add CD 13 inhibitor, such as ubenimex, and it will give us a new therapy to treat CD 13-positive leukemia cells. Such research will be important to circumvent resistance or side effects. Liposome technologies for doxorubicin or cisplatin will give us less side effects. Small molecules that interferes cell cycle will be researched quickly.

収録刊行物

  • Drug delivery system

    Drug delivery system 17(2), 113-118, 2002-03-10

    日本DDS学会

参考文献:  34件中 1-34件 を表示

各種コード

  • NII論文ID(NAID)
    10008132200
  • NII書誌ID(NCID)
    AN10084591
  • 本文言語コード
    JPN
  • 資料種別
    REV
  • ISSN
    09135006
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ